Valuation: Evotec SE

Market Cap 68Cr 79Cr 64Cr 58Cr 110.06Cr 7.53TCr 111.82Cr 755.36Cr 294.89Cr 3.77TCr 296.4Cr 289.98Cr 13TCr P/E 2026 *
-3.91x
P/E 2027 * -8.95x
Enterprise Value 83Cr 95Cr 78Cr 71Cr 133.04Cr 9.11TCr 135.17Cr 913.03Cr 356.45Cr 4.56TCr 358.27Cr 350.51Cr 15TCr EV / Sales 2026 *
1.38x
EV / Sales 2027 * 1.17x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-7.92%
1 week+3.38%
Current month+4.05%
1 month-28.21%
3 months-21.85%
6 months-42.64%
Current year-34.90%
1 week 3.45
Extreme 3.446
3.88
1 month 3.18
Extreme 3.176
3.88
Current year 3.18
Extreme 3.176
6.73
1 year 3.18
Extreme 3.176
7.3
3 years 3.18
Extreme 3.176
23.44
5 years 3.18
Extreme 3.176
45.83
10 years 3.18
Extreme 3.176
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Date Insider Type Main position Quantity % Market Cap.
30/01/26 Fiscal year

Chief Technology Officer

6,760 0.0038%
30/01/26 Tax

Chief Technology Officer

3,653 0.0021%
09/12/25 Buy

Chairman

20,000 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
-7.84%+3.38%-44.82%-83.76% 79Cr
+1.17%+1.09%+4.03%+15.90% 4.87TCr
-1.27%+2.71%+463.29%+577.27% 4.4TCr
-0.93%+7.90%+15.72%+74.33% 4.08TCr
-0.59%+3.15%+26.03%+8.92% 3.98TCr
0.00%+6.15%+23.03%+48.00% 3.27TCr
-1.54%0.00%+25.00%+120.24% 1.67TCr
-3.08%-1.05% - - 1.68TCr
+0.72%+0.31%+4.94%+21.57% 1.39TCr
-1.38%+5.94%+81.46%+29.68% 1.36TCr
Average -1.48%+4.56%+66.52%+90.24% 2.68TCr
Weighted average by Cap. -0.55%+3.68%+97.87%+134.55%

Financials

2026 *2027 *
Net sales 60Cr 69Cr 56Cr 51Cr 96Cr 6.6TCr 98Cr 661.91Cr 258.41Cr 3.31TCr 259.73Cr 254.11Cr 11TCr 72Cr 83Cr 68Cr 62Cr 116.01Cr 7.94TCr 117.87Cr 796.17Cr 310.83Cr 3.98TCr 312.42Cr 305.65Cr 13TCr
Net income -18Cr -20Cr -16Cr -15Cr -28Cr -1.93TCr -29Cr -193.55Cr -76Cr -966.46Cr -76Cr -74Cr -3.22TCr -5.88Cr -6.79Cr -5.51Cr -5.03Cr -9.46Cr -647.61Cr -9.61Cr -65Cr -25Cr -324.18Cr -25Cr -25Cr -1.08TCr
Net Debt 14Cr 16Cr 13Cr 12Cr 23Cr 1.57TCr 23Cr 157.68Cr 62Cr 787.34Cr 62Cr 61Cr 2.63TCr 16Cr 19Cr 15Cr 14Cr 26Cr 1.79TCr 26Cr 179Cr 70Cr 893.8Cr 70Cr 69Cr 2.98TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
13/26/13 3.548 -7.84% 15,93,179
12/26/12 €3.850 +3.89% 7,03,552
11/26/11 €3.706 +1.37% 6,23,911
10/26/10 €3.656 +5.54% 14,74,753
07/26/07 €3.464 +0.93% 6,96,995
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.850EUR
Average target price
4.586EUR
Spread / Average Target
+19.11%

Quarterly revenue - Rate of surprise